Probucol increases cholesteryl ester transfer protein activity in hypercholesterolaemic patients

Area of Science:

• Cardiovascular Science
• Pharmacology
• Lipid Metabolism

Background:

• Probucol is a lipid-lowering medication known to decrease low-density lipoprotein (LDL) and high-density lipoprotein (HDL) levels.
• Its proposed mechanisms include preventing LDL oxidation and enhancing reverse cholesterol transport.
• Tissue lipid deposits can regress with probucol treatment in both animal models and humans.

Purpose of the Study:

• To investigate the effect of probucol on cholesteryl ester transfer protein (CETP) activity.
• To determine the relationship between probucol dosage, CETP activity, and HDL-cholesterol levels.
• To elucidate the role of CETP in probucol-induced lipoprotein changes.

Main Methods:

• Administration of probucol to 10 hypercholesterolemic patients.
• Measurement of plasma probucol levels and CETP activity.
• Statistical analysis of the correlation between drug levels, CETP activity, and HDL-cholesterol.

Main Results:

• Probucol administration increased CETP activity by 50% in patients.
• Increased CETP activity showed a significant positive correlation with plasma probucol levels.
• CETP activity was inversely related to HDL-cholesterol levels, suggesting CETP stimulation causes HDL reduction.

Conclusions:

• Probucol may directly stimulate the synthesis and/or release of CETP.
• The observed reduction in HDL-cholesterol is likely a consequence of CETP stimulation.
• Enhanced reverse cholesterol transport via CETP activation is a key mechanism for probucol's effects on plasma lipoproteins.